<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059681</url>
  </required_header>
  <id_info>
    <org_study_id>S225/612</org_study_id>
    <nct_id>NCT02059681</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)</brief_title>
  <acronym>RECARDIO</acronym>
  <official_title>Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether endocavitary intramyocardial injection of&#xD;
      autologous bone-marrow-derived CD133+ cells is safe on the basis of number of adverse events,&#xD;
      with follow-up assessments extending up to 1 year after enrolment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase I study investigating the safety and preliminary efficacy of&#xD;
      endocavitary injection of bone-marrow-derived CD133+ cells in 15 patients with ischemic heart&#xD;
      failure (IHF) not eligible for conventional revascularization. Patients eligible will undergo&#xD;
      bone-marrow aspiration. On the day following bone-marrow aspiration patients will undergo&#xD;
      fluoroscopy-based endocavitary intramyocardial injections of the target areas previously&#xD;
      identified by gated-SPECT/CMR. CD133+ cells suspended in physiological saline supplemented&#xD;
      with 5% human albumin solution will be injected into the myocardium via the endocardial&#xD;
      route.&#xD;
&#xD;
      After discharge, efficacy follow-up will last 6-months safety follow-up (FU) will be extended&#xD;
      up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>The primary objective of this study will be to evaluate whether endocavitary intramyocardial injection of autologous bone-marrow-derived CD133+ cells is safe on the basis of number of adverse events, with follow-up assessments extending up to 1 year after enrolment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the effects of autologous CD133+ cells as assessed before and 6-months after injection on a) regional myocardial perfusion on the basis of stress gated-SPECT and CMR when available; b) functional capacity on the basis of peak VO2 consumption at CPET.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Chronic Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Autologous bone marrow derived-CD133+ cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD133+ cells (1-12x10^6) suspended in 10 ml physiological saline supplemented with 5% human albumin solution will be injected into the myocardium via the endocardial route; the whole 10 ml solution will be divided into 15-20 injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous bone marrow derived-CD133+ cells</intervention_name>
    <description>Cell therapy</description>
    <arm_group_label>Autologous bone marrow derived-CD133+ cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ischemic heart failure not amenable to any type of revascularization procedure&#xD;
             (percutaneous or surgical) as determined by one interventional cardiologist and one&#xD;
             cardiovascular surgeon,&#xD;
&#xD;
          2. Canadian Cardiovascular Society Angina functional class III to IV angina and/or&#xD;
             symptoms of heart failure (NYHA score IIb to IV) under state-of-the-art maximal&#xD;
             medical therapy,&#xD;
&#xD;
          3. Left Ventricular Ejection Fraction between 20% and 45%,&#xD;
&#xD;
          4. Peak V02 ≤ 21 mL/Kg/min,&#xD;
&#xD;
          5. Presence of a reversible perfusion defect ≥ 10% of the left ventricular myocardium (at&#xD;
             least 2 segments over 20) as determined by gated-SPECT, 6.18 years ≤ Age ≤ 75 years,&#xD;
&#xD;
        7.Hemodynamic stability, 8.Ability to accomplish a cardiopulmonary exercise testing, 9.Are&#xD;
        not pregnant and do not plan to become pregnant during the study. Females with childbearing&#xD;
        potential must provide a negative pregnancy test within 1-7 days before intervention and&#xD;
        must be using oral or injectable contraception (non-childbearing potential is defined as&#xD;
        post-menopausal for at least 1 year or surgical sterilization or hysterectomy at least 3&#xD;
        months before study start), 10.A signed consent form that has been approved by the&#xD;
        institutional review board.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A high-risk acute coronary syndrome (ACS) or a myocardial infarction in the past 3&#xD;
             months,&#xD;
&#xD;
          2. Presence of a documented unstable angina,&#xD;
&#xD;
          3. Left ventricular thrombus, as documented by echocardiography,&#xD;
&#xD;
          4. Evidence of a life-threatening arrhythmia,&#xD;
&#xD;
          5. Presence of any severe mitral valve disease requiring valve replacement or&#xD;
             reconstruction,&#xD;
&#xD;
          6. Presence of a mechanical aortic valve,&#xD;
&#xD;
          7. Presence of stenosis of the aortic valve, graded as ≥+2 equivalent to an orifice area&#xD;
             of 1,5 cm2 or less,&#xD;
&#xD;
          8. Presence of moderate to severe insufficiency of the aortic valve,&#xD;
&#xD;
          9. A left ventricular wall thickness of &lt;8 mm at the target site for cell injection, as&#xD;
             assessed by 2-D echocardiography and/or cardiac MRI,&#xD;
&#xD;
         10. Have a known, serious radiographic contrast allergy,&#xD;
&#xD;
         11. Contraindications to bone-marrow aspiration,&#xD;
&#xD;
         12. Be an organ transplant recipient,&#xD;
&#xD;
         13. Have liver dysfunction, as evidenced by enzymes (AST,ALT) &gt;3x the upper limits of&#xD;
             normals,&#xD;
&#xD;
         14. Severe renal failure (creatinine plasma levels &gt; 2.5 mg/dl),&#xD;
&#xD;
         15. A bleeding diathesis (defined as an INR greater than 1,5 not because of a reversible&#xD;
             cause, i.e. warfarin),&#xD;
&#xD;
         16. Have an hematologic abnormality without other explanation,&#xD;
&#xD;
         17. Apparent infection (c-reactive protein (CPR)&gt;30 mg/L, fever &gt; 37 °C),&#xD;
&#xD;
         18. An infectious-disease test result positive for human immunodeficiency virus (HIV),&#xD;
             hepatitis B, or hepatitis C, treponema pallidum (VDRL), HTLV 1 and 2,&#xD;
&#xD;
         19. Previous or current documented history of leukemia, myeloproliferative or myeloplastic&#xD;
             disorders,&#xD;
&#xD;
         20. Have a cardiac condition that limits lifespan to &lt;1 y,&#xD;
&#xD;
         21. A history of malignancy in the past 5 years,&#xD;
&#xD;
         22. Have a history of drug or alcoholic abuse within the past 24 months,&#xD;
&#xD;
         23. Be on chronic therapy with immunosuppressants,&#xD;
&#xD;
         24. Pregnant or lactating status,&#xD;
&#xD;
         25. Any condition that, in the judgment of the investigator, would place the patient at&#xD;
             undue risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giulio Pompilio, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino, IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giulio Pompilio, MD PhD</last_name>
    <phone>+39 02 58002562</phone>
    <email>giulio.pompilio@ccfm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatrice Bassetti, MSc</last_name>
    <phone>+39 02 58002027</phone>
    <email>beatrice.bassetti@ccfm.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felice Achilli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Felice Achilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino, IRCCS</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulio Pompilio, MD PhD</last_name>
      <phone>+39 02 58002562</phone>
      <email>giulio.pompilio@ccfm.it</email>
    </contact>
    <contact_backup>
      <last_name>Corrado Carbucicchio, MD</last_name>
      <phone>+39 02 58002616</phone>
      <email>corrado.carbucicchio@ccfm.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giulio Pompilio, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastiano Marra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sebastiano Marra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Giulio Pompilio</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

